The Oncology Institute, Inc. TOI Other Receivables
Other Receivables at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s other receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s other receivables?
- The Oncology Institute, Inc. (TOI) reported other receivables of $1.32M in Q1 2026.
- How has The Oncology Institute, Inc.'s other receivables changed year-over-year?
- The Oncology Institute, Inc.'s other receivables increased by 280.3% year-over-year, from $346K to $1.32M.
- What is the long-term trend for The Oncology Institute, Inc.'s other receivables?
- Over 5 years (2020 to 2025), The Oncology Institute, Inc.'s other receivables has grown at a 23.3% compound annual growth rate (CAGR), from $113K to $322K.
- What does other receivables mean?
- This represents miscellaneous claims for cash or other assets not classified under standard trade accounts receivable. It often includes tax refunds, interest receivables, or non-core operational claims. Monitoring this helps identify potential hidden liquidity issues or delays in cash conversion.